272 results on '"Luo, Peihua"'
Search Results
2. Dabrafenib alleviates hepatotoxicity caused by lenvatinib via inhibiting the death receptor signaling pathway
3. Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis
4. Development and safety of PI3K inhibitors in cancer
5. Crizotinib induces pulmonary toxicity by blocking autophagy flux in alveolar epithelial cells
6. Dasatinib causes keratinocyte apoptosis via inhibiting high mobility group Box 1-mediated mitophagy
7. Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors
8. Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation
9. Defining therapeutic targets for renal fibrosis: Exploiting the biology of pathogenesis
10. Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib
11. Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma
12. Keratinocytes apoptosis contributes to crizotinib induced-erythroderma
13. DKVMN-KAPS: Dynamic Key-Value Memory Networks Knowledge Tracing with Students’ Knowledge-Absorption Ability and Problem-Solving Ability
14. s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand–foot skin reaction that can be reversed by nicotinamide
15. Inhibition of PRKAA/AMPK (Ser485/491) phosphorylation by crizotinib induces cardiotoxicity via perturbing autophagosome-lysosome fusion.
16. The Frontline of Alternatives to Animal Testing: Novel In vitro Skin Model Application in Drug Development and Evaluation
17. High-mobility group box 1 protein-mediated necroptosis contributes to dasatinib-induced cardiotoxicity
18. HMGB1 contributes to adriamycin-induced cardiotoxicity via up-regulating autophagy
19. Chloroquine Intervenes Nephrotoxicity of Nilotinib through Deubiquitinase USP13‐Mediated Stabilization of Bcl‐XL
20. An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer
21. TEMPORARY REMOVAL: Crizotinib induces pulmonary toxicity by blocking autophagy flux in alveolar epithelial cells
22. Supplementary Methods and Figure Legend from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis
23. Supplementary Figure 4 from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis
24. Supplementary Figure 3 from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis
25. Supplementary Figure 2 from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis
26. Supplementary Figure 1 from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis
27. Supplemental Methods from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis
28. Supplemental Tables from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis
29. Supplemental Figures and Legends from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis
30. JAK-STAT signaling as an ARDS therapeutic target: Status and future trends
31. Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress
32. PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications
33. The participation of non-canonical autophagic proteins in the autophagy process and their potential as therapeutic targets
34. Anlotinib suppresses lung adenocarcinoma growth via inhibiting FASN-mediated lipid metabolism
35. Regorafenib inhibits EphA2 phosphorylation damages the liver via ERK/MDM2/p53 axis
36. JAK-STAT signaling as an ARDS therapeutic target: status and future trends
37. Reduced HMGB1 expression contributed to lapatinib-induced cutaneous injury
38. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
39. Structure-Based Rational Design Enables Discovery of a New Selective and Potent Akt Degrader with Improved Dermatologic Safety
40. Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors
41. Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib
42. Discovery of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity
43. Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway
44. Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib.
45. Regulation of p53 stability as a therapeutic strategy for cancer
46. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies
47. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
48. Hepatotoxicity of FDA-approved small molecule kinase inhibitors
49. PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1)
50. Involvement of mitogen-activated protein kinase in signal transducer and activator of transcription-1 mediated differentiation induced by bortezomib in acute myeloid leukemia cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.